These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 15634000

  • 1. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
    Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB, Hancock AA.
    J Med Chem; 2005 Jan 13; 48(1):38-55. PubMed ID: 15634000
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
    Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA.
    J Pharmacol Exp Ther; 2005 Apr 13; 313(1):176-90. PubMed ID: 15608077
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA.
    J Pharmacol Exp Ther; 2005 Apr 13; 313(1):165-75. PubMed ID: 15608078
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M, Zhao C, Gfesser GA, Thiffault C, Miller TR, Marsh K, Wetter J, Curtis M, Faghih R, Esbenshade TA, Hancock AA, Cowart M.
    J Med Chem; 2005 Oct 06; 48(20):6482-90. PubMed ID: 16190774
    [Abstract] [Full Text] [Related]

  • 5. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
    Cowart M, Gfesser GA, Browman KE, Faghih R, Miller TR, Milicic I, Baranowski JL, Krueger KM, Witte DG, Molesky AL, Komater VA, Buckley MJ, Diaz GJ, Gagne GD, Zhou D, Deng X, Pan L, Roberts EM, Diehl MS, Wetter JM, Marsh KC, Fox GB, Brioni JD, Esbenshade TA, Hancock AA.
    Biochem Pharmacol; 2007 Apr 15; 73(8):1243-55. PubMed ID: 17371699
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA.
    Biochem Pharmacol; 2004 Sep 01; 68(5):933-45. PubMed ID: 15294456
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist.
    Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD.
    J Pharmacol Exp Ther; 2012 Oct 01; 343(1):233-45. PubMed ID: 22815533
    [Abstract] [Full Text] [Related]

  • 8. Structure-activity relationships of arylbenzofuran H3 receptor antagonists.
    Gfesser GA, Faghih R, Bennani YL, Curtis MP, Esbenshade TA, Hancock AA, Cowart MD.
    Bioorg Med Chem Lett; 2005 May 16; 15(10):2559-63. PubMed ID: 15863316
    [Abstract] [Full Text] [Related]

  • 9. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
    Zhao C, Sun M, Bennani YL, Gopalakrishnan SM, Witte DG, Miller TR, Krueger KM, Browman KE, Thiffault C, Wetter J, Marsh KC, Hancock AA, Esbenshade TA, Cowart MD.
    J Med Chem; 2008 Sep 11; 51(17):5423-30. PubMed ID: 18683917
    [Abstract] [Full Text] [Related]

  • 10. Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.
    Tao M, Aimone LD, Huang Z, Mathiasen J, Raddatz R, Lyons J, Hudkins RL.
    J Med Chem; 2012 Jan 12; 55(1):414-23. PubMed ID: 22107017
    [Abstract] [Full Text] [Related]

  • 11. Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
    Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA.
    Inflamm Res; 2005 Apr 12; 54 Suppl 1():S23-4. PubMed ID: 15928819
    [No Abstract] [Full Text] [Related]

  • 12. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Tedford CE.
    J Pharmacol Exp Ther; 1999 May 12; 289(2):1151-9. PubMed ID: 10215699
    [Abstract] [Full Text] [Related]

  • 13. Effects of the histamine H₃ receptor antagonist ABT-239 on cognition and nicotine-induced memory enhancement in mice.
    Kruk M, Miszkiel J, McCreary AC, Przegaliński E, Filip M, Biała G.
    Pharmacol Rep; 2012 May 12; 64(6):1316-25. PubMed ID: 23406742
    [Abstract] [Full Text] [Related]

  • 14. Achievement of behavioral efficacy and improved potency in new heterocyclic analogs of benzofuran H3 antagonists.
    Cowart M, Faghih R, Gfesser G, Curtis M, Sun M, Zhao C, Bennani Y, Wetter J, Marsh K, Miller TR, Krueger K, Pan JB, Drescher K, Fox GB, Esbenshade TA, Hancock AA.
    Inflamm Res; 2005 Apr 12; 54 Suppl 1():S25-6. PubMed ID: 15928820
    [No Abstract] [Full Text] [Related]

  • 15. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE.
    Brain Res; 2005 May 31; 1045(1-2):142-9. PubMed ID: 15910772
    [Abstract] [Full Text] [Related]

  • 16. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
    Medhurst AD, Briggs MA, Bruton G, Calver AR, Chessell I, Crook B, Davis JB, Davis RP, Foley AG, Heslop T, Hirst WD, Medhurst SJ, Ociepka S, Ray A, Regan CM, Sargent B, Schogger J, Stean TO, Trail BK, Upton N, White T, Orlek B, Wilson DM.
    Biochem Pharmacol; 2007 Apr 15; 73(8):1182-94. PubMed ID: 17276409
    [Abstract] [Full Text] [Related]

  • 17. Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup.
    Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R, Hancock AA, Decker MW.
    Behav Brain Res; 2002 Apr 01; 131(1-2):151-61. PubMed ID: 11844582
    [Abstract] [Full Text] [Related]

  • 18. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
    Hancock AA, Diehl MS, Faghih R, Bush EN, Krueger KM, Krishna G, Miller TR, Wilcox DM, Nguyen P, Pratt JK, Cowart MD, Esbenshade TA, Jacobson PB.
    Basic Clin Pharmacol Toxicol; 2004 Sep 01; 95(3):144-52. PubMed ID: 15447739
    [Abstract] [Full Text] [Related]

  • 19. 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
    Black LA, Nersesian DL, Sharma P, Ku YY, Bennani YL, Marsh KC, Miller TR, Esbenshade TA, Hancock AA, Cowart M.
    Bioorg Med Chem Lett; 2007 Mar 01; 17(5):1443-6. PubMed ID: 17169555
    [Abstract] [Full Text] [Related]

  • 20. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F, Stephensen H, Peschke B, Rimvall K.
    J Med Chem; 2005 Jan 13; 48(1):306-11. PubMed ID: 15634025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.